Technology driven climate
solutions for agriculture.
Reducing livestock methane
emissions.

Rumin8’s strength is its expertise from the pharmaceutical industry in reproducing and stabilising otherwise volatile bioactive compounds found in nature.

We are applying our patent-protected technology and proprietary expertise in our mission towards a climate-optimal food system.

Our technology stabilizes the compounds found in certain plants to develop a range of feed supplements that specifically target the methanogenic pathways in livestock rumen.

By reducing ruminant methane, we enable the animal to convert this otherwise lost energy into compounds that can be utilised productively by the animal, resulting in increased animal productivity and creating a compelling value proposition for farmers.

Reproducing the target compound from the plant, rather than mass producing the plant itself, means agriculture, the world’s oldest industry, is providing solutions to address today’s climate challenges.

Board and management

Dr Stewart Washer

Co-founder & Chairman

Dr Stewart Washer

Co-founder & Chairman

 

Stewart has 25 years of CEO and ASX Board experience in medical technology and biotech companies. He is currently the Chairman of Emyria Ltd (ASX:EMD), a real world evidence and digital health company with Australian Clinics, Chairman of Orthocell Ltd (ASX:OCC), a regenerative medicine company dedicated to providing innovative treatments for people suffering from nerve and tendon injuries with products approved in Australia, Europe and US, Founding Chairman and current Director of Cynata Therapeutics Ltd (ASX:CYP) who are developing stem cell therapies in Australia and the UK. He was also a Co-Founder of Zelira Therapeutics Ltd (ASX:ZLD) who are developing medical cannabis products.

Stewart was previously the CEO of Calzada Ltd (ASX:PNV), the founding CEO of Phylogica Ltd (ASX:PYC) and before this, he was CEO of Celentis and managed the commercialisation of research from AgResearch in New Zealand with 650 Scientists and $130m revenues. This included a number of nutraceutical products. He was also a founder of a NZ$120m New Zealand based life science fund and Venture Partner with the Swiss based Inventages Nestlé Fund. He was an Investment Director with Bioscience Managers.

Stewart has held a number of Board positions in the past including Founding Chairman of Hatchtech Pty Ltd that sold in 2015 for A$279m, Director of iCeutica Pty Ltd that sold for over $60m to a US Pharma and a Director of AusBiotech Ltd, the Federal industry body. He was also a Senator with Murdoch University.

David Messina

Co-founder & CEO

David Messina

Co-founder & CEO

 

David is a successful international executive with proven entrepreneurial skills and track record in developing and managing businesses in agriculture, energy and biotech, holding positions at the board and in executive management with both start-ups and mature businesses.

Previously, David was the CEO of Seed Grain Biotechnology Australia, Planttech Pty Ltd, Central EU Biofuels Ltd, Hutton Energy and most recently Whitebark Energy. He is currently the Chairman of Cadogan Estates Australia, owner of large farming properties in WA.

David was born and raised on a family farm in WA and has an excellent understanding of both the challenges and opportunities facing Australian farmers and producers. David is uniquely placed to realise the commercial development of the Rumin8 technology.

Elaine Darby

Co-founder & Director

Elaine Darby

Co-founder & Director

 

Elaine brings to Rumin8 her diverse experience in science, communications and law. Her previous roles included a lawyer with top tier corporate law firm Clayton Utz, Media and Communications Officer for an Australian Federal Member of Parliament and Managing Director and Senior Winemaker of Aquila Estate Winery. She was an award winning wine-maker and was also involved in international business development and marketing in Singapore, Japan, Canada, the United Kingdom and the United States.

More recently, Elaine was an investment director of Biologica Ventures Pty Ltd and founding CEO of cannabinoid pharmaceutical company AusCann Group Ltd (ASX:AC8). She currently serves as Director of Goldwood Investments and Managing Director of Aquila Black Limited, a technology company developing innovative solutions for the food and beverage sector.

Elaine has overseen the development of various novel IP delivery systems of volatile plant derived compounds for stable, scalable pharmaceutical, food and beverage products.

Samantha Tough

Independent Director

Samantha Tough

Independent Director

 

Samantha has a broad and varied career in many sectors including energy, resources, engineering and agriculture. She also has a 20 plus year career serving on boards.

Samantha is Pro Vice-Chancellor Industry Engagement at the University of Western Australia and currently serves as Chair of Horizon Power, Director Clean Energy Finance Corporation, Chair COAG National Energy Selection Panel, Director Fluence Ltd, Director Mineral Carbonation Ltd.

Samantha’s previous directorships include Saracen Mineral Holdings Ltd, Synergy, CBH, Retail Energy Market Company Ltd, Structerre Pty Ltd, Cape plc, Aerison Pty Ltd, Murchison Metals Ltd, Southern Cross Goldfields Ltd, Strike Resources Ltd, WA Academy of Performing Arts. Samantha’s executive roles include General Manager North West Shelf Woodside Energy Ltd, Director Strategy of Hardman Resources Ltd, Senior Vice President Natural Resources Commonwealth Bank and Director of the Pilbara Power Project.

Samantha completed a Bachelor of Laws and Bachelor of Jurisprudence at UWA and worked as a barrister and solicitor before progressing to the commercial sector. She is a Fellow of the Australian Institute of Company Directors.

Matt Callahan

Co-founder

Matt Callahan

Co-founder

 

Matt is an experienced life sciences and health tech executive based in Philadelphia, USA. He has been the founding CEO or founding Executive Director of several companies including iCeutica Inc (sold to private equity), Churchill Pharmaceuticals Inc (sold to Sun Pharmaceuticals), Dimerix Biosciences Ltd (ASX:DMX), Respirion Pharmaceuticals Pty Ltd, Botanix Pharmaceuticals Ltd (ASX:BOT), Emyria Ltd (ASX:EMD) and Orthocell Ltd (ASX:OCC). He has raised more than $200M in private and public capital for his companies and has advised on numerous fund raisings, mergers and acquisitions and other asset transactions.

He has led the development of five products that have received FDA approval and been successfully launched in the US and international markets, and has more than 25 years legal, IP and investment management experience. Mr Callahan has worked as an investment director for two venture capital firms investing in life sciences, technology and other sectors, and was the general manager of Australian listed technology and licensing company that created Nearmap (ASX:NMP).

Dr Cameron Scadding

Co-founder

Dr Cameron Scadding

Co-founder

 

Cameron is a forensic and analytical chemist, and a globally recognised and respected expert in his discipline with extensive complex forensic investigation experience.

Cameron has specific experience and expertise in supply chain integrity, security and managing supply chain risks and is regularly invited to speak on trends in supply chain integrity, specifically around agri-food, the food supply chain, food fraud, transparency, trust, traceability and provenance. Cameron’s supply chain and forensic skill set have made him a leading consultant and leader in the emerging global cannabis industry with cannabis clients ranging from cultivars, processors, cannabinoid pharmaceutical companies and governments.

Cameron has developed a range of food and pharmaceutical products. These include a number of new to world solid dose form pharmaceuticals and a range of functional foods and beverages. In addition to Cameron being the principal scientist and developer of these new to world products he also supported his clients with market entry and the development of a trusted and high integrity supply chain.

Cameron is the founder and current Managing Director of Australian based science and technology business Source Certain International (SCI). SCI operates a forensic, analytical and research and development laboratory in Perth, Western Australia.

Dr Silke Jacques

Chief Technology Officer

Dr Silke Jacques

Chief Technology Officer

 

Dr Silke Jacques has over 10 years of global work experience in research, project management and personnel management in Belgium, Korea and Australia.

She began her research career at Ghent University (Belgium) completing a PhD in Biochemistry and Biotechnology in 2014. As a Junior Professor, she then joined and established the start-up of a Belgian university branch campus together with three American Universities in Songdo, South-Korea. Dr Jacques lectured Virology, set-up the practical courses in Microbiology and established a functional research lab focusing on marine bioactives from seaweed to stimulate plant growth.

More recently, she spent the last 5 years in Australia, focusing on agricultural research both at government institutions (CSIRO) and universities (Curtin University) mainly focusing on crop protection. In her role with Rumin8, Silke combines her scientific, communication and project management skills, built through collaboration with government, industry and universities, with her passion for innovative entrepreneurship.

Kosta Stavreas

Chief Commercial Officer

Kosta Stavreas

Chief Commercial Officer

 

Kosta is a business strategy and innovation expert. He has spent his career working alongside the leadership teams of Fortune 500 companies to develop growth strategy, invent novel products and services, and build business lines. His experience spans value creation across a diverse array of industries, including renewable energy, natural resources, consumer electronics, financial services, B2B software, pharmaceuticals, and hospitality, and has deep knowledge of the strategy and innovation practices employed spanning startup companies through to global multi-nationals.

Notable clients include Samsung, Sony, Dunkin Donuts, Wells Fargo, MunichRe, Cox Communications and AngloGold Ashanti. He has spent most of his career in the Unites States, where he founded Maneas, a strategy consulting and technology development practice based in New York; lead innovation teams at Fahrenheit 212; held operational leadership roles in early stage companies; and has helped dozens of startups sharpen their strategy, raise capital and commercialize their technologies.

Dr Martin Auldist

Head of Field Trials

Dr Martin Auldist

Head of Field Trials

 

Martin graduated from Latrobe University in Melbourne, Australia, in 1988 with a Bachelors degree in Agricultural Science (with Honours). He subsequently was awarded a PhD from the same institution in 1995 for his research into on-farm factors affecting the composition and suitability of milk for manufacturing.

Since then, Martin has amassed a further 25 years experience in applied dairy research, leading or overseeing dozens of experiments focusing on dairy cattle physiology and nutrition, and dairy farm management systems. He worked mostly as a Senior Research Scientist with the State Government at Ellinbank in Victoria, Australia, but has international experience having spent seven years at a dairy research centre in Hamilton, New Zealand (DairyNZ), and a further six months at Fermoy, Ireland (Teagasc Moorepark).

He has authored or co-authored 108 peer-reviewed papers in scientific journals (source: Scopus), two book chapters and many conference papers. Martin has supervised seven PhD students, a Masters student and two Honours students, and has in the last decade been appointed Honorary Principal Fellow at the University of Melbourne with the title of Associate Professor.

Menu